Quick Take
Precision BioSciences (DTIL) intends to raise $126 million in an IPO of its common stock, per an amended registration statement.
The company has created an advanced gene-editing platform for a variety of disease conditions and crop modification purposes.
DTIL has promising technology but the IPO has no investor support, and is richly valued.
Company & Technology
Durham, North Carolina-based Precision was founded in 2006 to develop what it calls its ARCUS gene-editing platform.
Management is headed by co-founder and CEO Matthew Kane, who has an educational background in biomedical engineering